Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2012 May;61(5):989-90.
doi: 10.2337/db12-0233.

GLP-1 receptor agonist effects on normal and neoplastic pancreata

Michael Goggins
Editorial

GLP-1 receptor agonist effects on normal and neoplastic pancreata

Michael Goggins. Diabetes. 2012 May.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the KrasG12D mouse model. Diabetes 2012;. 61:1250–1262 - PMC - PubMed
    1. Nyborg NC, Mølck AM, Madsen LW, Bjerre Knudsen L. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 2012. 61:1243–1249 - PMC - PubMed
    1. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150–156 - PMC - PubMed
    1. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137:482–488 - PMC - PubMed
    1. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide—the FDA’s review of a new antidiabetic therapy. N Engl J Med 2010;362:774–777 - PubMed

LinkOut - more resources